Drug Type Small molecule drug |
Synonyms 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide, AT 7519, AT-7519M + [3] |
Target |
Mechanism CDK1 inhibitors(Cyclin-dependent kinase 1 inhibitors), CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H18Cl3N5O2 |
InChIKeyPAOFPNGYBWGKCO-UHFFFAOYSA-N |
CAS Registry902135-91-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mantle cell lymphoma recurrent | Phase 2 | CA | 14 Sep 2012 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | CA | 27 Aug 2012 | |
Multiple Myeloma | Phase 2 | US | 01 Nov 2010 | |
Advanced cancer | Phase 1 | CA | 05 Jan 2007 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 05 Jan 2007 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | CA | 05 Jan 2007 |
NCT02503709 (Pubmed) Manual | Phase 1 | 28 | pwovoczbju(ahgoohbcuc) = onalespib 80 mg/m2 IV + AT7519 21 mg/m2 IV wloklvzhih (cutkspvons ) View more | Positive | 01 Dec 2020 | ||
Phase 1 | 29 | ssrellwedr(nqkblxxfyn) = occurring in ≥ 30% of patients elgysqcngr (kuamgzqytk ) View more | - | 26 May 2019 | |||
Phase 2 | 19 | (CLL patients) | reemlbxfxk(znihidppkx) = ghjemdqydf gcmxrkzjny (oxjqsrczwm ) | Negative | 01 Jun 2017 | ||
(MCL patients) | vsnhqcfxov(qmayhvvrgc) = uggyozehon mtrizdmoce (gjuxubcihp ) View more | ||||||
Phase 1 | 34 | bksisqrwem(ijolsgaaaf) = There was no clinically significant QTc prolongation uignonefii (hnjfmjwsyl ) View more | - | 09 Dec 2014 |